Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2012 Apr 27;10:79. doi: 10.1186/1479-5876-10-79

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright ©2012 Kunos et al.; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

3-aminopyridine-2-carboxyaldehyde-thiosemicarbazone (3-AP) effectively restored cisplatin sensitivity in “platinum-resistant” SKOV3 and OVCAR3 ovarian cancer cells. Panel A: Cells were treated with cisplatin (5 μM) and/or 3-AP (5 μM) for 6 hours and assayed by MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) for cell mitochondrial viability at 24 hours after the start of cisplatin exposure. Compared to cisplatin alone, 3-AP alone, and 3-AP preceding cisplatin treatment, a significant cisplatin plus 3-AP interaction was found (P < 0.01, star). Panel B: 14-day clonogenic ovarian cancer cell survival was done using cisplatin (5 μM) and a wider therapeutic range of 3-AP (1, 5, or 10 μM). Here too a significant cisplatin plus 3-AP enhancement of cytotoxicity was seen (P < 0.001, star), when compared to 3-AP alone or 3-AP preceding cisplatin. Means (± standard error) are reported.